We stress two important considerations for future studies when evaluating management tools: direct measures of human behavior as a response, and application of rigorous experimental design.
While the impact of survey modality on responses has been well documented when studying topics of sensitive nature, such as HIV [29], the topic has not been rigorously studies when evaluating SRHS.
In future studies when evaluating the efficacy of tumor antigen specific vault nanocaspsules vaccination routes in the protective and therapeutic settings that include i.v or i.p. delivery routes, changes in plasma/serum transaminase level will be quantified for vault effects on liver function.
Early non-invasive detection of anti-proliferative activity with 18F-FLT PET could also be useful in a clinical setting to determine whether patients are responsive to conventional treatment and during phase I, II and III studies when evaluating responses to new anti-cancer drugs.
More generally, the tendency for smaller studies to show a greater effect than larger studies, when evaluating interventions, has been named small-study effects [ 4].
It is not scientifically justifiable to ignore the valid evidence contained in observational studies when evaluating therapeutic interventions, particularly for emerging indications [ 41, 43– 47, 49, 49– 56, 56– 60].
Action research has been used in a number of health care studies when evaluating change in practice [ 13, 14] and specifcally in service improvement initiatives for stroke [ 15– 17].
We observed an overall placebo effect of 25%, which reached over 50% in two-thirds of the women, emphasizing the need for well conducted, double-blind, randomized, placebo-controlled studies when evaluating novel treatments for pain.
The need to pursue "individualized" therapy was clearly accelerated from the findings of the Action to Control Cardiovascular Risk in Diabetes (ACCORD), Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE), and Veterans Affairs Diabetes Trial (VADT) studies when evaluating cardiovascular end points (2 4).
The Spectron EF femoral stem was more stable than the Charnley flanged 40 stem in our study when evaluated at 2 years.
